.2
J.P. Morgan Presentation January 13, 2025
Forward Looking Statements and Disclaimer The presentation contains
forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential,” “should,” “could,” “aim,” “estimate,” “predict,” “continue” and similar expressions or the
negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. We intend these forward-looking statements to
be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including express and implied statements relating to
the commercial success of Attruby, the timing of ongoing clinical trials, including BridgeBio Oncology Therapeutics’ and Gondola Bio’s clinical trials, the clinical, therapeutic and market potential of our clinical development programs and
our pipeline, BridgeBio Oncology Therapeutics’ pipeline and Gondola Bio’s pipeline, our speed of creating new and meaningful drugs and related impact on patients, the efficiency of our engine to rapidly and efficiently deliver medicines, our
value creation potential for patients, the potential market sizes and opportunities, the safety, efficacy and mechanisms of our newly FDA-approved Attruby (acoramidis) and other later-stage products including infigratinib, BBP-418 and
encaleret, the timing of approval of Attruby for ATTR-CM in the European Union and Japan, our financial position, including our expectations regarding reaching regulatory milestones and the receipt of milestone payments, the potency and
safety of our product candidates, the potential benefits of our product candidates, the potential for greater patient access to medications, the affordability and availability of insurance coverage of our medications, and the timing and
expectations regarding results of our various clinical trials, reflect our current views about our plans, intentions, expectations and strategies, which are based on the information currently available to us and on assumptions we have made.
Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions
about the Company, including, without limitation, risks inherent in developing therapeutic products, and those risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed
with the U.S. Securities and Exchange Commission (“SEC”) and in subsequent filings made by the Company with the SEC, which are available on the SEC’s website at www.sec.gov. In light of these risks and uncertainties, many of which are beyond
the Company’s control, the events or circumstances referred to in the forward-looking statements, express or implied, may not occur. The actual results may vary from the anticipated results and the variations may be material. You are
cautioned not to place undue reliance on these forward-looking statements, which speak to the Company’s current beliefs and expectations only as of the date of the presentation. Except as required by law, the Company disclaims any intention
or responsibility for updating or revising any forward-looking statements made or presented at the presentation in the event of new information, future developments or otherwise. No representation is made as to the safety or effectiveness of
the product candidates for the therapeutic use for which such product candidates are being studied. Certain information communicated at the presentation may relate to or is based on studies, publications, surveys and other data obtained
from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of the presentation, it has not independently verified, and makes no
representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, certain information to be communicated at the presentation involves a number of assumptions and
limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, such research has not been verified by any independent source. Such information is provided as of the date of the presentation and is
subject to change without notice. The Company has not verified, and will not verify, any part of this presentation, and the Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information
to be communicated at the presentation or as to the existence, substance or materiality of any information omitted from the presentation at the presentation. The Company disclaims any and all liability for any loss or damage (whether
foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this document or the related presentation and such liability is expressly disclaimed.
Key recent achievements: clinical impact
Key recent achievements: 3 fully enrolled Phase 3 trials Trial enrolled 112
patients to evaluate BBP-418 in Limb-Girdle Muscular Dystrophy 2I/R9 Trial enrolled 70 participants to evaluate encaleret in Autosomal Dominant Hypocalcemia Type 1 Trial enrolled 114 participants to evaluate infigratinib in
Achondroplasia NEW INFORMATION
Key recent achievements: regulatory advancement for late-stage
programs Receives Breakthrough Designation (BTD) for Achondroplasia Receives Rare Pediatric Disease Designation (RPDD) for Limb-Girdle Muscular Dystrophy 2I/R9 Receives Regenerative Medicine Advanced Therapy Designation (RMAT) for Canavan
Disease Infigratinib BBP-418 BBP-812
Key recent achievement: Attruby regulatory approval Indicated for the treatment
of adult patients with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization
Remarkable commercial momentum 430 Attruby Scripts NEW INFORMATION
BridgeBio’s growth is underpinned by an innovative corporate model, as
highlighted in a recent publication Applications of Portfolio Theory to Accelerating Biomedical Innovation Neil Kumar, Andrew W. Lo, Chinmay Shukla,and Brian Stephenson Operational nimbleness Centralized infrastructure for functions with
economies of scale Hyper-focused and agile decision making Creative financing toolkit Toolkit of strategic options (asset & portfolio levels) Costs are variablized and flexible across central functions and affiliates World class,
decentralized R&D Leverage hyper-experienced, science-focused R&D practitioners Asset-level incentives preserve biology-level focus Diversified portfolio Uncorrelated assets enable multiple “shots on goal” Modality and
therapeutic area agnostic selection of programs
The BridgeBio ecosystem has a dynamic pipeline of
products Program Indication Pre-clinical Phase 1 Phase 2 Phase 3 Approved Patients (US + EU) Market Oppty Estimated US LOE** Attruby (acoramidis) Transthyretin Amyloidosis
(ATTR-CM) 500,000+ $20B+ 2039 Infigratinib Achondroplasia (ACH) Fully Enrolled 55,000+ $2B+ 2041 Hypochondroplasia (HCH) 55,000+ $2B+ 2041 BBP-418 Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Fully
Enrolled 7,000+ $1B+ 2041 Encaleret Autosomal Dominant Hypocalcemia Type 1 (ADH1) Fully Enrolled 25,000+ $1B+ 2041 Post-Surgical Hypoparathyroidism (PSH) 200,000+ $1B+ 2044 BBP-812 Canavan Disease 1,000 TBD 2039 BridgeBio
Oncology Therapeutics Oncology, various Various Various Various GondolaBio Rare disease, various Various Various Various Phase 1/2 Pivotal 45% ownership* 38% ownership* * BridgeBio Oncology Therapeutics and GondolaBio are
separate, independent companies from BridgeBio. BridgeBio’s initial interest in GondolaBio is subject to reduction as additional tranches of capital contributions are funded. ** Approximate estimated US LOE dates considering various factors
including issued patents, pending patent applications, potential patent term extensions, and regulatory exclusivities.
Market growth drivers include: With more sponsors, there is expanding disease
awareness Increased global adoption of non-invasive diagnostic tools Global annual ATTR market sales1 $B 2019 2020 2021 2022 2023 2024 Peak Year $6.4 $15-$202 +57% 1ATTR market includes all approved drugs for ATTR-PN and
ATTR-CM. 2024 sales annualized as of Q3 2024. 2Consensus estimates of $15B-$20B ATTR market. ATTR is a multi-billion-dollar market primed for continued expansion . . .
+ Compelling Clinical Data 1 Market Access: Make it Easy 2 The way we
win
The most rapid benefit seen in any Phase 3 study of ATTR-CM to date In
composite of all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30 In the cumulative frequency of cardiovascular-related hospitalization events at Month 30 3 Months 42% Reduction 50% Reduction Key
Data 1
Data: Attruby achieved near-complete stabilization of TTR 1Maurer, M. et al.,
Eur. Heart Jour, 2024;45(Suppl 1). 2Nelson, L. et al., Amyloid, 2021;28(1):24-29. 3Penchala, S. et al., PNAS, 2013;110(24):9992-97. Preclinical signals of superior potency & selectivity “We carried out the subunit exchange in human
plasma to address the relative selectivity of AG10 [acoramidis] vs. tafamidis…it is obvious that tafamidis is inferior to AG10 [acoramidis], but nothing like the degree you claim it is.” –Prof. Jeffery Kelly (inventor of tafamidis) in email
correspondence with Dr. Isabella Graef, February 27, 2013. 1 Differential TTR selectivity “It is clear that AG10 [acoramidis] binds more selectively to TTR in serum than tafamidis.” 3 Evidence of potency on TTR stabilization “AG10
[acoramidis] is 4 times more potent than tafamidis at a fixed plasma concentration (e.g., 10 μM).” 2 Increase in serum TTR levels reflect in vivo stabilization “Change from baseline in serum TTR levels were higher in participants receiving
acoramidis only than those receiving placebo+tafamidis at Month 30...”1
Make it easy: simplified, differentiated, generous access programs 28-day
supply for patients new to Attruby (newly diagnosed or switching from another therapy) Independent and rare/orphan disease–focused Specialty Pharmacies (SPs) where Institutional SPs can keep prescription Dedicated Attruby Field
Reimbursement Managers and Patient Access Liaisons Easily accessible Copay and Patient Assistance Program Free Trial Distribution Network Field Access Teams Patient Assistance Programs Commitment to clinical trial patients US patients
who participated in the acoramidis clinical trials may receive Attruby at no cost for the duration of their medically indicated treatment 2
Performance to date indicates strong commercial momentum 430 Attruby scripts
written to date 248 Unique prescribing HCPs 77% Medicare lives in equal formulary position to tafamidis
You priced responsibly and have a good label; we will have you at parity with
tafamidis. Also, I have never seen a company offer free drug to their trial patients. Shows commitment.” - Payer “ You did the right thing by being less than tafamidis… both your label and price will play a role here.” - Payer “ I
want to reemphasize our gratitude for LDN inclusion. We objectively see key metrics in the patient journey improve as a result of dispensing access…Eager to leverage our resources to impact patient care in a positive way.” –Manager of
Health System SP “ You are a smart company to set up your distribution this way. I wish all companies would do this!” – Director of Health System SP “ “BridgeBio’s thoughtful resources and the structure of the network…aligns with the
health system's mission of putting patients first. – Pharmacist "Holy Smokes!? I wish all manufacturers would provide this information. Do you have any idea how much time this is going to save our team? – Pharmacist “Given the
combination of strong efficacy and safety data, alongside BridgeBio’s very health system friendly approach towards access for this product (in comparison to the many challenges we have had with Pfizer…), we plan to begin preferring Attruby.
– AD Specialty Clinical Program Development “It takes less than 5 minutes- the easiest enrollment process of any drug we use. – RN Heart Failure Coordinator “ Pricing: Limited Distribution Network: ForgingBridges: “ “ “ Positive
feedback all around on Market Access:
Scott Collins SVP, Market Access Ana Merz VP, Sales Launched IMBRUVICA
($5B+, 12 FDA approvals, 6 disease states, 7 indications in 10 years) and EPKINLY (3L+ DLBCL) Liz Arnold Head of Commercial Strategy Multiple global launches, expertise in strategy, consulting, and marketing across rare disease,
hematology, and OTC Sean Doherty SVP, Marketing Broad global sales and marketing launch experience including in rare, infectious, and auto-immune diseases Hudson Boyer VP, Commercial Analytics & Ops Launches in rare disease,
hematology, and immunology; strategy consulting and equity analyst background Extensive market access experience with consistent coverage acrossrare disease and oncology, leading large field-based access teams Julie Everett Chief Business
Officer Successfully led cross-functional teams through multiple rare disease launches, including VOXZOGO and PALYNZIQ (BioMarin) Led commercial strategy/execution across ~$1B portfolio ~Decade of strategy consulting leadership focused on
launch excellence and lifecycle maximization (Trinity) John Whang Chief Medical Affairs Officer Orchestrated multiple successful launches with pioneering therapies in competitive segments – STELARA (Janssen), REPATHA (Amgen), and CAMZYOS
(BMS) 8+ launches as strategy consultant (McKinsey) Demonstrated strategic innovation (Heartline Study – J&J / Apple collab) and consistently built outstanding organizations Matt Outten Chief Commercial Officer Broad commercial
leadership expertise with success across multiple competitive markets Led $5B+ portfolio, 12 FDA approvals spanning 6 disease states and 7 indications (IMBRUVICA, Pharmacyclics) Commercial lead on $21B pharma M&A deal Our BridgeBio
team is committed to providing industry-leading access and white glove service for all parties looking to bring Attruby to patients with ATTR-CM. Our Attruby team has experienced industry leaders who have built and launched blockbuster
drugs
Looking Ahead: Attruby Delivers Outstanding Results in Patients with Poor
Prognosis Median Survival (months) ATTRwt-CM ATTRv-CM (V122I) V122I ATTRv-CM has an aggressive phenotype and poor prognosis1 N = 413 Statistically significant benefit on composite ACM or first CVH in ATTRv-CM participants vs.
placebo2 N (%) Hazard Ratio (95% CI) p value Overall Population 611 (100%) 0.65 (0.50-0.83) 0.0008 ATTRv-CM 59 (9.7%) 0.41 (0.21-0.81) 0.0109 Natural History ATTRibute-CM mITT Population N = 413 1Razvi, Y. et al., Eur Jour
Heart Fail., 2024;26(2):383-393. 2BridgeBio Data on File. Overall population and ATTRv-CM data vs. placebo.
1Hornstrup, L.. et al. Arterioscler Thromb Vasc Biol, 2013;33:1441-47. 2Figure
adapted from Christoffersen, M. et al., JAMA Cardiology, 2024. Hazard ratio (95% CI) TTR distribution Additional data: Elevated TTR levels are associated with improved survival Higher TTR concentration associated with greater life
expectancy (N≈102K individuals)2 Genetic stabilization of transthyretin associated with improved health outcomes (N≈69K individuals)1 - WT - T119M Carriers
Infigratinib
Design Criteria 55,000+ People In the US/EU with achondroplasia (ACH), the
most common form of disproportionate short stature. 55,000+ People In the US/EU with hypochondroplasia (HCH), another form of disproportionate short stature. Impact Opportunity Phase 2 Data $4B+ Market Opportunity Infigratinib is an
oral best-in-class FGFR3 inhibitor that targets achondroplasia and hypochondroplasia at their source Annualized height velocity (To the sponsor’s knowledge, largest effect reported to date) Target FGFR3-driven skeletal dysplasias at their
source Proportionality (To the sponsor’s knowledge, largest effect reported to date) Demonstrate safety with low dosing Well-tolerated Convenient oral ROA to reduce patient burden
Key Secondary Endpoints: Change from baseline in height z-score Change from
baseline in upper to lower body segment ratio Primary Endpoint: Change from baseline in annualized height velocity at Wk 52 Screening and Observational Period Children are followed for a minimum of 6 months Randomization 2:1 (N = 114)
Open Label Extension Children are followed until adult height is reached 0.25 mg/kg/day Infigratinib (N ~ 76) 6 months Placebo (N ~ 38) 12 months Phase 3 Trial Fully Enrolled; LPLV Expected 2H 2025 We have fully enrolled a Phase 3
study (PROPEL 3) of Infigratinib in Achondroplasia with LPLV in 2H 2025
BBP-418
Design Criteria 7,000+ Patients In the US/EU with LGMD2I/R9, a progressive
neuromuscular disorder that leads to loss of ambulation, cardiomyopathy, and respiratory dysfunction. Impact Opportunity Phase 2 Data BBP-418 is a first-in-class, disease-modifying therapy positioned to be the first approval in any form of
limb-girdle muscular dystrophy Glycosylated αDG (Expected surrogate endpoint) Serum creatine kinase Stabilization of clinical measures Well-tolerated Targets the LMGD2I/R9 at its source by adding substrate to restore glycosylation
of αDG Avoid safety concerns by using a synthesized version of an endogenous compound Convenient oral ROA to reduce patient burden $1B+ Market Opportunity + additional opportunity with other forms of LGMD
Screening Genetically confirmed, symptomatic LGMD2I/R9 12-60 years of
age Randomization 2:1 (N ~ 112) Open Label Extension BBP-418 (N ~ 75) BBP-418 (N ~ 75) Placebo (N ~ 37) Placebo (N ~ 37) 12 months 24 months Final Analysis Endpoints: NSAD (primary) Ambulatory measures 10MWT 100MTT Pulmonary
function: FVC Upper limb function: PUL 2.0 QoL measures Interim Endpoints: Glycosylated αDG (primary) Serum creatine kinase (CK) Trends in clinical measures Interim Analysis Topline Data 2H 2025 We have fully enrolled a Phase 3 study
(FORTIFY) of BBP-418 in LGMD2I/R9 and expect topline interim analysis data readout in 2H 2025 Phase 3 Trial Fully Enrolled; LPLV & Topline Results Expected 2H 2025
Encaleret
Design Criteria 25,000+ Patients In the US/EU with ADH1, a genetic disease
resulting in the disruption of Ca homeostasis. 200,000+ Patients In the US/EU with Post-Surgical Hypoparathyroidism (PSH), a dysregulation of Ca homeostasis caused by impaired parathyroid function. Impact Opportunity Phase 2
Data Encaleret is a first-in-class, disease-modifying investigational therapy with potential to be the first approved intervention for ADH1 Parathyroid hormone to normal range Serum calcium to normal range Well-tolerated Urine calcium
to normal range Target ADH1 at its source by desensitizing over-active Ca sensing receptors Normalize PTH, serum Ca, and urine Ca levels Convenient oral ROA to reduce patient burden $2B+ Market Opportunity
Select Secondary Endpoints: Blood iPTH, 1,25-(OH)2 Vitamin D, magnesium, and
phosphate Urine magnesium and phosphate Bone turnover markers Renal ultrasound and renal function ER/urgent care visits and/or hospitalizations Quality of life (SF-36) Primary Endpoint: Proportion of participants achieving: Blood Ca
within the target range AND 24-hour urine Ca within the reference range Screening and SoC Optimization Period Age > 16 years of age Documented pathogenic variant, or variant of uncertain significance, of the CASR gene associated with
biochemical findings related to hypoparathyroidism SoC Maintenance Period (N ~ 70) Randomization 2:1 2-14 days Long-Term Extension Encaleret Encaleret Titration Period (N ~ 47) Encaleret Maintenance Period 4 weeks SoC Titration
Period (N ~ 23) SoC Maintenance Period 20 weeks 4 weeks SoC = standard of care; a combination of oral activated Vitamin D and/or calcium supplements. CASR = calcium-sensing receptor gene. Phase 3 Trial Fully Enrolled; LPLV &
Topline Results Expected 2H 2025 We have fully enrolled the Phase 3 study (CALIBRATE) of encaleret in ADH1 and expect topline results in 2H 2025 Up to 4 years
BBP-812Canavan Disease
BBP-812 has the potential to change the disease trajectory for children with
Canavan, a severe, ultra-rare, autosomal recessive leukodystrophy “One patient in particular is sitting independently and taking steps and walking, and that is certainly something I’ve never seen with Canavan disease.” – Dr. Florian
Eichler, Mass General Hospital for Children “[The participant] was like a new child, reactive, holding hands, and clapping.” – Dr Annette Bley, University Medical Center Hamburg “Lots of improvement at 3-month visit, emotional presence,
visual tracking, reaching for things” – Dr. Alexander Fay, UCSF Benioff Children's Hospital Safety data consistent with other AAV9 GTx’s Urine NAA levels Preliminary Data CNS NAA levels Gross Motor Skills Developmental Skills
BridgeBio Ecosystem Highlights
BBOT has progressed two potentially first-in-class molecules into the clinic
with a third expected in 1H 2025 Program Mechanism of Action Status BBO-8520 KRASG12C ON / OFF First direct inhibitor of KRASG12C ON Inhibits both KRASG12C GTP (active) and GDP (inactive) states Differentiates from KRASG12C GDP
(inactive)-only inhibitors Enrolling BBO-10203 RAS:PI3Kα Breaker Blocks specific interaction between RAS and PI3Ka RAS driver agnostic (KRAS, HRAS and NRAS) Selectively blocks PI3K / AKT effector signaling in the tumor No hyperglycemia
/ hyperinsulinemia Enrolling BBO-11818 PanKRAS ON / OFF Direct inhibitor of KRASG12X ON Potent panKRAS inhibitor Directly binds mutant KRAS IND exp. Q1 2025
Indication Discovery Lead Optimization IND Enabling Phase 1 Est. Patient
Pop. (US + EU) Erythropoietic Protoporphyria (EPP) 20k Galactosemia 10k Alpha-1 Antitrypsin Deficiency (AATD) 200k Neurofibromatosis Type 1 (NF1) 200k Hereditary Pancreatitis 30k Fibrous Dysplasia 50k Congenital Glycosylation
Disorder Type Ia (PMM2-CDG) 5k Autosomal Dominant Polycystic Kidney Disease (ADPKD) 300k Tuberous Sclerosis Complex 1/2 (TSC) 65k Genetic Epilepsy Driven by SynGAP1 Mutations 10k The GondolaBio pipeline features a diverse set of
programs across TAs
We are well-financed and expect to hit numerous milestones in 2025 vision for
2030: >$8B De-risked PYS >100k lives Lives impacted Acoramidis: EU approval Acoramidis: Japan approval Q1 Earnings Call Q2 and Q3 Earnings Calls Encaleret: LPLV, Topline BBP-418: LPLV, Topline Infigratinib: LPLV + 1H
2025 2H 2025